Developing next-generation clinical and preclinical small molecule therapies that harness the body's natural restorative processes.
Dedicated to addressing unmet clinical needs with innovative biological and therapeutic solutions.
Focused on small molecule pan-caspase and caspase-selective inhibitors designed to protect key biological structures and restore critical immune function.
Leveraging proprietary hypoxia-based cell culture technology to create hypoxia-induced proteins and extracellular matrix materials that stimulate cellular repair.
By simulating embryonic conditions of low oxygen and suspension culture, Histogen enables cells to naturally produce key growth factors and proteins necessary for tissue regeneration.
Transforming regenerative science into scalable therapeutic solutions for infectious and inflammatory diseases.